Sloan-Kettering Cancer Center Now Offering Access Pharma’s (OTCBB: ACCP) MuGard

Northern, WI 4/4/12 (StreetBeat) -- Expanding its footprint in cancer treatment, Access Pharmaceuticals, Inc. (OTCBB: ACCP) said today that Memorial Sloan-Kettering Cancer Center (MSKCC), one of the world's premier cancer centers, has added MuGard to its cancer supportive care pharmacy formulary. Patients undergoing cancer treatment will now have direct access to MuGard from the first day of cancer treatment to manage oral mucositis, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.

Oral mucositis is a significant health issue for all cancer patients with more than 40 percent of all patients citing it as one of the most bothersome side effects of radiotherapy and chemotherapy. Head and neck cancer patients are especially at risk of oral mucositis with incident rates in excess of 90 percent.

"Having a world-renowned institution like Memorial Sloan-Kettering add MuGard to its formulary is a monumental step in our mission to increase MuGard access for cancer patients," said Frank Jacobucci, Vice President Sales and Marketing, Access Pharmaceuticals, Inc. He continued, "Dedicated to the progressive control and cure of cancer, MSKCC is considered one of the best cancer treatment institutions in the world and we are pleased that it has taken action, after their evaluation of MuGard, to treat and potentially eliminate oral mucositis, a debilitating side effect that is often times detrimental to anticancer treatments and lessens the quality of life for cancer patients.

Access Pharma also gave a reminder about a conference call for today which was held at 11 AM EDT. Those who did not attend can listen to a replay of the call starting on April 4, 2012 at 1:00 pm ET, through April 18, 2012 until 11:59 pm ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Access Pharmaceuticals (ACCP) Presenting Poster at 10th Annual Diabetes Technology Meeting

Access Pharmaceuticals, a bio-pharmaceutical company engaged in using proprietary drug-delivery technologies to develop new therapies for oncology, cancer supportive care and diabetes, is presenting a poster today at the 10th Annual Diabetes Technology Meeting entitled, "Preclinical Studies with Cobalamin™ Nanoparticles for Oral Drug Delivery of Insulin." The Meeting is taking place at the Marriott Bethesda North in Bethesda, Maryland. The focus of the poster is to review ongoing developments of Access’ oral insulin formulation, which has recently been re-branded as CobOral™ after making advances with the technology.

Getting medication through the gastrointestinal tract and into the bloodstream presents a great challenge to scientists and this simple fact is that this barrier is one of the reasons that many diabetics are still injecting insulin subcutaneously. CobOral is addressing this issue and making significant strides in their development of CobOral™ as research in animal models has shown Cobalamin™-coated insulin-loaded nanoparticles given orally provide a glucose lowering effect which is slower in onset and longer in duration than injected insulin.

This is only one of the areas of unmet need that CobOral addresses. There are countless pharmaceutical active ingredients cannot be delivered by the oral route because of poor absorption of the drug in the stomach and/or degradation in the gastrointestinal tract. Access released news at the end of October that they have entered into a pre-licensing feasibility agreement with a leading bio-pharmaceutical company to develop an oral formulation of an undisclosed prostate cancer compound utilizing its proprietary vitamin B-12-based CobOral™ Drug Delivery Technology.

While most of us in this world, this author included, are not scientists and certainly have a difficult time understanding the chemistry behind biotechnological innovations and the processes behind them, it is not “smashing atoms” to understand that oral medications are far-and-away the popular mode of drug delivery. The diabetic population alone presents an enormous opportunity for Access to capitalize with successful development of this technology, without giving consideration to cancer therapies and the many other applications for which CobOral can benefit the medical community.

More information on Access Pharmaceutical, its drugs in development, its proprietary drug delivery platforms and the investment opportunity presented by ACCP can be found on the Company’s website at www.accesspharma.com.

More information on the 10th Annual Diabetes Technology Meeting at which Access is presenting can be found at www.diabetestechnology.org.


Legal Notice / Disclaimer

This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. Andrew Klips (“the author”) has based this document on information obtained from sources he believes to be reliable, but which has not been independently verified; the author makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the author only and are subject to change without notice. The author assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, the author assumes no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information provided within this Report.

The author does not own shares of Access Pharmaceuticals.